Physician profile
Lee E Leinwetter
NPI 1841412376
$7,235.81
in general payments reported to CMS, 2019-2025
50 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $274 · 2021: $501 · 2022: $1,156 · 2023: $1,258 · 2024: $1,340 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,569.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.79 | 2021-2025 | |
| Pfizer INC. | $766.34 | 2021-2025 | |
| Amgen INC. | $579.43 | 2019-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $573.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $490.37 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $455.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $380.55 | 2019-2020 | |
| Glaxosmithkline, LLC. | $274.81 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $256.25 | 2019-2025 | Belsomra, Verquvo, Gardasil 9 |
| Abbott Laboratories | $226.36 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $208.77 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.45 | 2019-2025 | Ofev, Jardiance |
| Axsome Therapeutics, INC. | $154.32 | 2024-2025 | Auvelity, Symbravo |
| Novartis Pharmaceuticals Corporation | $150.71 | 2019-2025 | |
| Astellas Pharma US INC | $150.03 | 2019-2025 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Leinwetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.